These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 540209)

  • 21. Noradrenergic and dopaminergic interrelation in schizophrenia.
    Brambilla F; Marini S; Saito A; Fassone G; Picardi A; Nerozzi D; Pancheri P
    Psychiatry Res; 1994 Sep; 53(3):231-42. PubMed ID: 7870845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hormone ontogeny in the ovine fetus. XV. Studies of adenohypophysial hormones after fetal pituitary stalk section: evidence for an extrahypothalamic dopaminergic influence on fetal prolactin secretion.
    Gluckman PD; Leisti S; Kaplan SL; Grumbach MM
    Endocrinology; 1983 May; 112(5):1624-30. PubMed ID: 6403331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological manipulation of anterior pituitary dopamine content in the male rat: relationship to serum prolactin concentration and lysosomal enzyme activity.
    Demarest KT; Riegle GD; Moore KE
    Endocrinology; 1984 Aug; 115(2):493-500. PubMed ID: 6745164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The direct effect of reserpine in vitro on prolactin release from rat anterior pituitary glands.
    Login IS; MacLeod RM
    Brain Res; 1981 Jan; 204(1):79-85. PubMed ID: 7248756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of naloxone or levallorphan on serum prolactin concentrations and apomorphine-induced growth hormone secretion.
    Lal S; Nair NP; Cervantes P; Pulman J; Guyda H
    Acta Psychiatr Scand; 1979 Feb; 59(2):173-9. PubMed ID: 420037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopaminergic stimulation of prolactin release.
    Denef C; Manet D; Dewals R
    Nature; 1980 May; 285(5762):243-6. PubMed ID: 6154895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Responses of prolactin and growth hormone to L-tryptophan infusion: effects in normal subjects and schizophrenic patients receiving neuroleptics.
    Cowen PJ; Gadhvi H; Gosden B; Kolakowska T
    Psychopharmacology (Berl); 1985; 86(1-2):164-9. PubMed ID: 2991963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prolactin (PRL) receptor induction in cultured rat hepatocytes: dual regulation by PRL and growth hormone.
    Barash I; Cromlish W; Posner BI
    Endocrinology; 1988 Mar; 122(3):1151-8. PubMed ID: 3342748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of lithium on hypothalamic-pituitary dopaminergic function.
    Lal S; Nair NP; Guyda H
    Acta Psychiatr Scand; 1978 Jan; 57(1):91-6. PubMed ID: 636903
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interaction of SCH 23390, a D-1-selective antagonist, with the anterior pituitary D-2 receptors and prolactin secretion in the rat.
    Apud JA; Masotto C; Ongini E; Racagni G
    Eur J Pharmacol; 1985 Jun; 112(2):187-93. PubMed ID: 2863153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of dopamine on the altered release of prolactin, luteinizing hormone, and follicle-stimulating hormone induced by interleukin-2 in vitro.
    Karanth S; Marubayashi U; McCann SM
    Neuroendocrinology; 1992 Dec; 56(6):871-80. PubMed ID: 1369597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time-dependent increase in plasma prolactin after pituitary stalk section: role of posterior pituitary dopamine.
    Murai I; Garris PA; Ben-Jonathan N
    Endocrinology; 1989 May; 124(5):2343-9. PubMed ID: 2495929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating prolactin response to dopamine agonists in schizophrenia. Methodological problems.
    Davis BM; Davis KL; Mohs RC; Mathé AA; Rothpearl AB; Johns CA; Levy MI; Horvath TB
    Arch Gen Psychiatry; 1985 Mar; 42(3):259-64. PubMed ID: 3977547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroendocrine responses to apomorphine in depressed patients and healthy control subjects.
    Jimerson DC; Cutler NR; Post RM; Rey A; Gold PW; Brown GM; Bunney WE
    Psychiatry Res; 1984 Sep; 13(1):1-12. PubMed ID: 6595680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroendocrine tests during treatment with neuroleptic drugs. III. Plasma growth hormone and prolactin responses to apomorphine.
    Kolakowska T; Gelder M; Fraser S
    Br J Psychiatry; 1981 Nov; 139():408-12. PubMed ID: 6120733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The tyrosine hydroxylase-human growth hormone (GH) transgenic mouse as a model of hypothalamic GH deficiency: growth retardation is the result of a selective reduction in somatotrope numbers despite normal somatotrope function.
    Kineman RD; Aleppo G; Frohman LA
    Endocrinology; 1996 Nov; 137(11):4630-6. PubMed ID: 8895326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The preovulatory prolactin surge: an evaluation of the role of dopamine.
    Arbogast LA; Ben-Jonathan N
    Endocrinology; 1988 Dec; 123(6):2690-5. PubMed ID: 3264239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of clozapine on apomorphine-induced growth hormone secretion and serum prolactin concentrations in schizophrenia.
    Nair NP; Lal S; Cervantes P; Yassa R; Guyda H
    Neuropsychobiology; 1979; 5(3):136-42. PubMed ID: 431802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Schneider's first-rank symptoms of schizophrenia. An association with increased growth hormone response to apomorphine.
    Whalley LJ; Christie JE; Brown S; Arbuthnott GW
    Arch Gen Psychiatry; 1984 Nov; 41(11):1040-3. PubMed ID: 6497565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppression of prolactin by dopamine agonists in schizophrenics and controls.
    Rotrosen J; Angrist B; Clark C; Gershon S; Halpers FS; Sachar EJ
    Am J Psychiatry; 1978 Aug; 135(8):949-51. PubMed ID: 665840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.